Pre-Clinical (Discovery and Development)

Find out how to fill up your pipeline and increase innovation. Pharma IQ is proud to provide an international, non-biased, central resource, for professionals working in early discovery and preclinical research to exchange ideas on best practice and share case studies on innovation within the area.
 

The Top 10 Pharmaceutical & Biotechnology R&D Investors

Contributor: Pharma IQ
Posted: 4/30/2014

The Top 10 Pharmaceutical & Biotechnology R&D Investors - Pharma IQ

Research based pharmaceutical companies are always striving to make advancements in science and technology, but this innovation comes at a price R&D investment. Research and development of new therapies involves a complex expensive, time-intensive and risk process. We take a closer look below at the Top 10 Pharmaceutical & Biotechnology R&D Investors in the world. Full Article »


Events related to this topic:

Utilising Big Data for Bioscience Product Development

Contributor: Diana Davis
Posted: 7/3/2014


Utilising Big Data for Bioscience Product Development - Diana Davis

Big data is turning up everywhere. In this Process Perspectives podcast, Kaare Buch Petersen, Information Architect in Global IT at Christen Hansen, a Denmark-based supplier of bioscience products to food and health industries, talks about how his company has been using big data in the development of their new products. Full Podcast »


Events related to this topic:

The Halo(gen) Effect in para-Substituted Phenyl Rings

Contributor: Jonas Boström
Posted: 2/26/2015


The Halo(gen) Effect in para-Substituted Phenyl Rings - Jonas Boström

One key to successfully progress a drug discovery project is to make first-rate decisions (hopefully) based on unambiguous data. This is not trivial since our scientific problems are often very complex and data can be fuzzy. In drug design we try to approach this uncertainty by being rational. It is however sometimes forgotten that our rational approaches may not be that rational after all – decisions may well be based on personal preferences and intuitive biases.... perhaps unconsciously made on biased data. Full Column »


Events related to this topic:

BioAscent Discovery Ltd on Using Compounds to Drive Collaboration

Large pharmaceutical companies, such as AstraZeneca, Bayer, GSK, Lilly and Johnson and Johnson, are investing significant resource into Open Innovation, in order to harness the technical and scientific resources of research groups with the company. It is not just large pharma who can understand the advantages of these initiatives, however the need for dedicated resources required to facilitate collaborations, can act as a barrier to smaller organisations. Read more, download the full whitepaper here. Full Whitepaper »


Events related to this topic:



Advertise With Us

Join the Pharmas IQ Community